Inactive Instrument

Press Releases Aevi Genomic Medicine Inc Nasdaq

Equities

US58436Q2030

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2020	Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index	CI
2020	Aevi Genomic Medicine, Inc. Announces Resignation of Directors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	20-02-03	AQ
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)	19-12-23	AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)	19-12-11	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	19-12-10	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	19-12-05	AQ
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)	19-11-22	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)	19-11-20	AQ
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination	19-10-15	PR
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody	19-08-07	PR
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference	19-08-06	PR
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor	19-07-15	PR
Aevi Genomic Medicine : Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD	19-01-02	PR
Aevi Genomic Medicine : to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD	18-11-26	PR
Aevi Genomic Medicine : Reports Third Quarter 2018 Financial Results and Provides Business Update	18-11-01	PR
Aevi Genomic Medicine : Announces Completion of Enrollment for Part B of the ASCEND Trial	18-10-15	PR
Aevi Genomic Medicine : to Present at the H.C. Wainwright 20th Annual Global Investment Conference	18-08-29	PR
Aevi Genomic Medicine : Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial	18-08-21	PR
Aevi Genomic Medicine : Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD	18-08-14	PR
Aevi Genomic Medicine : Reports Second Quarter 2018 Financial Results and Provides Business Update	18-08-02	PR
Aevi Genomic Medicine, Inc. : Announces Novel Co-crystal Version of AEVI-001	18-07-19	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aevi Genomic Medicine Inc Nasdaq

Equities

US58436Q2030

Press Releases

Filters